Challenges and pitfalls of combining targeted agents in phase I studies
- PMID: 18669449
- DOI: 10.1200/JCO.2008.17.2676
Challenges and pitfalls of combining targeted agents in phase I studies
Comment on
-
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
